Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer.
Yi ZhangSilvia K Tacheva-GrigorovaJanette SuttonZea MeltonYvonne S L MakCecilia LayBryan A SmithTao SaiThomas J Van BlarcomBarbra Johnson SasuSiler H PanowskiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
In summary, the preclinical efficacy and safety data presented here support further evaluation of DLL3 CAR T cells as potential clinical candidates for the treatment of SCLC.
Keyphrases
- small cell lung cancer
- induced apoptosis
- stem cell transplantation
- cell therapy
- cell cycle arrest
- bone marrow
- electronic health record
- big data
- cancer therapy
- brain metastases
- stem cells
- oxidative stress
- machine learning
- cell death
- mesenchymal stem cells
- signaling pathway
- high dose
- combination therapy
- artificial intelligence